Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 5, 2009, Pages 509-514

  Papadopoulos, Nicholas E ^a   Bedikian, Agop ^a   Ring, Sigrid ^a   Kim, Kevin B ^a   Hwu, Wen Jen ^a   Gerber, Donna L ^a   Homsi, Jade ^a   Hwu, Patrick ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapy; Melanoma; Paclitaxel

Indexed keywords

CISPLATIN; DACARBAZINE; PACLITAXEL;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; MALE; MAXIMUM PERMISSIBLE DOSE; MELANOMA; METASTASIS; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; OPTIMAL DRUG DOSE; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; TREATMENT RESPONSE; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DACARBAZINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70350662205     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181942a1f     Document Type: Article

References (23)

1. Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology (Huntingt). 1995;9:1149-1158.
2. Avril MF, Aamdal S, Grob JJ, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol. 2004;22:1118-1125.
3. Bedikian AY, Millward M, Pehamberger H, et al. The Oblimersen Melanoma Study Group. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma. J Clin Oncol. 2006;24:4738-4745.
4. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin- 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
5. Allen IE, Kupelnick B, Kumashiro M, et al. Efficacy of interleukin-2 in the treatment of metastatic melanoma. Cancer Ther. 1998;1:168-173.
6. Buzaid AC, Legha SS, Winn R, et al. Cisplatin (C), vinblastine (V), DTIC (D) (CVD) versus DTIC alone in metastatic melanoma: preliminary results phase III cancer community oncology program (CCOP) [abstract]. Proc ASCO. 1993;12. Abstract 1328.
7. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multi-center randomized trial of the Dartmouth regimen versus DTIC in patients with metastatic melanoma. J Clin Oncol. 1999;17:2745-2751.
8. Legha SS, Ring S, Papadopoulos N, et al. A phase II trial of Taxol in metastatic melanoma. Cancer. 1990;65:2478-2481.
9. Einzig AI, Hochster H, Wiernik PH, et al. A phase II study of Taxol in patients with malignant melanoma. Invest New Drugs. 1991;9:59-64.
10. Einzig AI, Wiernik PH, Wadler S, et al. Phase I study of paclitaxel (Taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy. Invest New Drugs. 1998;16:29-36.
11. Powderly J, Khan K, Richards J, et al. A 2-stage controlled phase 1/2 study of STA-4783 in combination with paclitaxel in patients with advanced metastatic melanoma [abstract]. Proc ASCO. 2005;23(suppl 16):725.Abstract 7561.
12. Bedikian AY, Plager C, Papadopoulos NE, et al. Phase II evaluation of paclitaxel by short intravenous infusion in metastatic melanoma. Melanoma Res. 2004;14:63-66.
13. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol. 1991;9:1692-1703.
14. Cummings FJ, Clark J, Santos-Moore A, et al. Paclitaxel plus cisplatin in previously-treated patients with metastatic tumors [abstract]. Proc ASCO. 1995;14:434.Abstract 1379.
15. Hodi FS, Soiffer RI, Clark I, et al. Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002;25:283-286.
16. Zimpfer-Rechner C, Hofmann U, Figl R, et al. Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the Dermatologic Co-operative Oncology Group (DeCOG). Melanoma Res. 2003;13:531-536.
17. Rao RD, Holtan SG, Ingle IN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006;106:375-382.
18. Flaherty KT, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. J Clin Oncol. 2004;22:14.Abstract 7507.
19. Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Proc ASCO. 2007;25:472.Abstract 8511.
20. World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: WHO; 1979.
21. Simon R. Optimal two-stage designs for Phase II Clinical Trials. Control Clin Trials. 1989;10:1-10.
22. Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and DTIC (CVD) for metastatic melanoma. Cancer. 1989;64:2024-2029.
23. Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine, and DTIC (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol. 1996;7: 827-835.